CD163 and glioma: Several studies have revealed that CD163+ TAM upregulation in solid tumors is associated with a short survival rate and lower responses to T-cell-based immunotherapy [96,97]; additionally, in a recent study, M2-polarized TAMs were found to be the only independent prognostic factor for gliomas among all TAMs [97].